GMI小孢子靈芝免疫調節蛋白質結合多種創新技術,
己取得結構,檢驗與多種應用專利,同時持續累積發表學術文獻並取得多項國際認證。
Abstract
Periprosthetic joint infections (PJIs) caused by Staphylococcus aureus infection are difficult to treat due to antibiotic resistance. It is known that the biofilms from methicillin-resistant S. aureus (MRSA) promote expansion of myeloid-derived suppressor cells (MDSCs) to suppress T-cell proliferation and benefit bacterial infections. This study finds that GMI, a fungal immunomodulatory peptide isolated from Ganoderma microsporum, suppresses MDSC expansion to promote the proliferation of cytotoxic T cells. The enhancement is likely attributed to increased expression of IL-6 and TNF-α and reduction in ROS expression. Similar beneficial effects of GMI on the suppression of MDSC expansion and IL-6 expression are also observed in the whole blood and reduces the accumulation of MDSCs in the infected bone region in a mouse PJI infection model. This study shows that GMI is potentially useful for treating S. aureus-induced PJIs.
資料來源1:https://doi.org/10.3390/ijms22136854
資料來源2. 台灣:小孢子靈芝免疫調節蛋白gmi能降低細菌感染誘發髓源性抑制細胞的增生,減少對T-細胞增生抑制的影響